1
|
Peixoto C, Joncour A, Temal-Laib T, Tirera A, Dos Santos A, Jary H, Bucher D, Laenen W, Pereira Fernandes A, Lavazais S, Delachaume C, Merciris D, Saccomani C, Drennan M, López-Ramos M, Wakselman E, Dupont S, Borgonovi M, Roca Magadan C, Monjardet A, Brys R, De Vos S, Andrews M, Jimenez JM, Amantini D, Desroy N. Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases. J Med Chem 2024; 67:5233-5258. [PMID: 38552030 PMCID: PMC11017251 DOI: 10.1021/acs.jmedchem.3c02246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 03/04/2024] [Accepted: 03/14/2024] [Indexed: 04/12/2024]
Abstract
The salt-inducible kinases (SIKs) SIK1, SIK2, and SIK3 belong to the adenosine monophosphate-activated protein kinase (AMPK) family of serine/threonine kinases. SIK inhibition represents a new therapeutic approach modulating pro-inflammatory and immunoregulatory pathways that holds potential for the treatment of inflammatory diseases. Here, we describe the identification of GLPG3970 (32), a first-in-class dual SIK2/SIK3 inhibitor with selectivity against SIK1 (IC50 of 282.8 nM on SIK1, 7.8 nM on SIK2 and 3.8 nM on SIK3). We outline efforts made to increase selectivity against SIK1 and improve CYP time-dependent inhibition properties through the structure-activity relationship. The dual activity of 32 in modulating the pro-inflammatory cytokine TNFα and the immunoregulatory cytokine IL-10 is demonstrated in vitro in human primary myeloid cells and human whole blood, and in vivo in mice stimulated with lipopolysaccharide. Compound 32 shows dose-dependent activity in disease-relevant mouse pharmacological models.
Collapse
|
2
|
Temal-Laib T, Peixoto C, Desroy N, De Lemos E, Bonnaterre F, Bienvenu N, Picolet O, Sartori E, Bucher D, López-Ramos M, Roca Magadán C, Laenen W, Flower T, Mollat P, Bugaud O, Touitou R, Pereira Fernandes A, Lavazais S, Monjardet A, Borgonovi M, Gosmini R, Brys R, Amantini D, De Vos S, Andrews M. Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312. J Med Chem 2024; 67:380-401. [PMID: 38147525 PMCID: PMC10788895 DOI: 10.1021/acs.jmedchem.3c01428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 11/24/2023] [Accepted: 11/28/2023] [Indexed: 12/28/2023]
Abstract
Salt-inducible kinases (SIKs) SIK1, SIK2, and SIK3 are serine/threonine kinases and form a subfamily of the protein kinase AMP-activated protein kinase (AMPK) family. Inhibition of SIKs in stimulated innate immune cells and mouse models has been associated with a dual mechanism of action consisting of a reduction of pro-inflammatory cytokines and an increase of immunoregulatory cytokine production, suggesting a therapeutic potential for inflammatory diseases. Following a high-throughput screening campaign, subsequent hit to lead optimization through synthesis, structure-activity relationship, kinome selectivity, and pharmacokinetic investigations led to the discovery of clinical candidate GLPG3312 (compound 28), a potent and selective pan-SIK inhibitor (IC50: 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3). Characterization of the first human SIK3 crystal structure provided an understanding of the binding mode and kinome selectivity of the chemical series. GLPG3312 demonstrated both anti-inflammatory and immunoregulatory activities in vitro in human primary myeloid cells and in vivo in mouse models.
Collapse
Affiliation(s)
- Taouès Temal-Laib
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Nicolas Desroy
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Elsa De Lemos
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Natacha Bienvenu
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Olivier Picolet
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Eric Sartori
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Denis Bucher
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | | | - Wendy Laenen
- Galapagos
NV, Generaal De Wittelaan
L11, A3, 2800 Mechelen, Belgium
| | - Thomas Flower
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Patrick Mollat
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Olivier Bugaud
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Robert Touitou
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | | | - Alain Monjardet
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Monica Borgonovi
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Romain Gosmini
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Reginald Brys
- Galapagos
NV, Generaal De Wittelaan
L11, A3, 2800 Mechelen, Belgium
| | - David Amantini
- Galapagos
SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Steve De Vos
- Galapagos
NV, Generaal De Wittelaan
L11, A3, 2800 Mechelen, Belgium
| | - Martin Andrews
- Galapagos
NV, Generaal De Wittelaan
L11, A3, 2800 Mechelen, Belgium
| |
Collapse
|
3
|
Lavazais S, Jargosch M, Dupont S, Labéguère F, Menet C, Jagerschmidt C, Ohm F, Kupcsik L, Parent I, Cottereaux C, Marsais F, Oste L, Van de Water A, Christophe T, De Vos S, Fallon P, Lauffer F, Clément-Lacroix P, Eyerich K, Brys R. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. Sci Transl Med 2023; 15:eabj3289. [PMID: 36791209 DOI: 10.1126/scitranslmed.abj3289] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Innate immunity not only shapes the way epithelial barriers interpret environmental cues but also drives adaptive responses. Therefore, modulators of innate immune responses are expected to have high therapeutic potential across immune-mediated inflammatory diseases. IRAK4 is a kinase that integrates signaling downstream of receptors acting at the interface between innate and adaptive immune responses, such as Toll-like receptors (TLRs), interleukin-1R (IL-1R), and IL-18R. Because effects of IRAK4 inhibition are stimulus, cell type, and species dependent, the evaluation of the therapeutic potential of IRAK4 inhibitors requires a highly translational approach. Here, we profiled a selective IRAK4 inhibitor, GLPG2534, in an extensive panel of models of inflammatory skin diseases, translationally expanding evidence from in vitro to in vivo and from mouse to human. In vitro, IRAK4 inhibition resulted in substantial inhibition of TLR and IL-1 responses in dendritic cells, keratinocytes, granulocytes, and T cells but only weakly affected dermal fibroblast responses. Furthermore, disease activity in murine models of skin inflammation (IL-23-, IL-33-, imiquimod-, and MC903-induced) was markedly dampened by IRAK4 inhibition. Last, inhibiting IRAK4 reversed pathogenic molecular signatures in human lesional psoriasis and atopic dermatitis biopsies. Over the variety of models used, IRAK4 inhibition consistently affected central mediators of psoriasis (IL-17A) and atopic dermatitis (IL-4 and IL-13). Overall, our data highlight IRAK4 as a central player in skin inflammatory processes and demonstrate the potential of IRAK4 inhibition as a therapeutic strategy in chronic inflammatory skin diseases.
Collapse
Affiliation(s)
| | - Manja Jargosch
- Department of Dermatology and Allergy, Technical University of Munich, 80802 Munich, Germany
| | | | | | | | | | - Frenz Ohm
- Department of Dermatology and Allergy, Technical University of Munich, 80802 Munich, Germany
| | | | | | | | | | - Line Oste
- Galapagos NV, 2800 Mechelen, Belgium
| | | | | | | | - Padraic Fallon
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 PN40 Dublin, Ireland
| | - Felix Lauffer
- Department of Dermatology and Allergy, Technical University of Munich, 80802 Munich, Germany
| | | | - Kilian Eyerich
- Department of Dermatology and Venerology, Medical Center-University of Freiburg, Freiburg, Germany
| | | |
Collapse
|
4
|
Labéguère F, Dupont S, Alvey L, Soulas F, Newsome G, Tirera A, Quenehen V, Mai TTT, Deprez P, Blanqué R, Oste L, Le Tallec S, De Vos S, Hagers A, Vandevelde A, Nelles L, Vandervoort N, Conrath K, Christophe T, van der Aar E, Wakselman E, Merciris D, Cottereaux C, da Costa C, Saniere L, Clement-Lacroix P, Jenkins L, Milligan G, Fletcher S, Brys R, Gosmini R. Discovery of 9-Cyclopropylethynyl-2-(( S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1- a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial. J Med Chem 2020; 63:13526-13545. [PMID: 32902984 DOI: 10.1021/acs.jmedchem.0c00272] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
GPR84 is a medium chain free fatty acid-binding G-protein-coupled receptor associated with inflammatory and fibrotic diseases. As the only reported antagonist of GPR84 (PBI-4050) that displays relatively low potency and selectivity, a clear need exists for an improved modulator. Structural optimization of GPR84 antagonist hit 1, identified through high-throughput screening, led to the identification of potent and selective GPR84 inhibitor GLPG1205 (36). Compared with the initial hit, 36 showed improved potency in a guanosine 5'-O-[γ-thio]triphosphate assay, exhibited metabolic stability, and lacked activity against phosphodiesterase-4. This novel pharmacological tool allowed investigation of the therapeutic potential of GPR84 inhibition. At once-daily doses of 3 and 10 mg/kg, GLPG1205 reduced disease activity index score and neutrophil infiltration in a mouse dextran sodium sulfate-induced chronic inflammatory bowel disease model, with efficacy similar to positive-control compound sulfasalazine. The drug discovery steps leading to GLPG1205 identification, currently under phase II clinical investigation, are described herein.
Collapse
Affiliation(s)
| | - Sonia Dupont
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Luke Alvey
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Florilène Soulas
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Gregory Newsome
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Amynata Tirera
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Vanessa Quenehen
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Thi Thu Trang Mai
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Pierre Deprez
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Roland Blanqué
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Line Oste
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | | | - Steve De Vos
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Annick Hagers
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Ann Vandevelde
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Luc Nelles
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Nele Vandervoort
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Katja Conrath
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | | | | | | | - Didier Merciris
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Céline Cottereaux
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Cécile da Costa
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | - Laurent Saniere
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| | | | - Laura Jenkins
- Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - Graeme Milligan
- Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - Stephen Fletcher
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Reginald Brys
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
| | - Romain Gosmini
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France
| |
Collapse
|
5
|
Puengel T, De Vos S, Hundertmark J, Kohlhepp M, Guldiken N, Pujuguet P, Auberval M, Marsais F, Shoji KF, Saniere L, Trautwein C, Luedde T, Strnad P, Brys R, Clément-Lacroix P, Tacke F. The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. J Clin Med 2020; 9:E1140. [PMID: 32316235 PMCID: PMC7231190 DOI: 10.3390/jcm9041140] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Revised: 04/05/2020] [Accepted: 04/14/2020] [Indexed: 12/17/2022] Open
Abstract
Medium-chain fatty acids (MCFAs) have been associated with anti-steatotic effects in hepatocytes. Expression of the MCFA receptor GPR84 (G protein-coupled receptor 84) is induced in immune cells under inflammatory conditions and can promote fibrogenesis. We aimed at deciphering the role of GPR84 in the pathogenesis of non-alcoholic steatohepatitis (NASH), exploring its potential as a therapeutic target. GPR84 expression is upregulated in liver from patients with non-alcoholic fatty liver disease (NAFLD), correlating with the histological degree of inflammation and fibrosis. In mouse and human, activated monocytes and neutrophils upregulate GPR84 expression. Chemotaxis of these myeloid cells by GPR84 stimulation is inhibited by two novel, small molecule GPR84 antagonists. Upon acute liver injury in mice, treatment with GPR84 antagonists significantly reduced the hepatic recruitment of neutrophils, monocytes, and monocyte-derived macrophages (MoMF). We, therefore, evaluated the therapeutic inhibition of GPR84 by these two novel antagonists in comparison to selonsertib, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, in three NASH mouse models. Pharmacological inhibition of GPR84 significantly reduced macrophage accumulation and ameliorated inflammation and fibrosis, to an extent similar to selonsertib. In conclusion, our findings support that GPR84 mediates myeloid cell infiltration in liver injury and is a promising therapeutic target in steatohepatitis and fibrosis.
Collapse
Affiliation(s)
- Tobias Puengel
- Department of Medicine III, RWTH-University Hospital Aachen, 52074 Aachen, Germany; (T.P.); (N.G.); (C.T.); (T.L.); (P.S.)
- Department of Hepatology & Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany; (J.H.); (M.K.)
| | - Steve De Vos
- Galapagos SA, 102 avenue Gaston Roussel, 93230 Romainville, France; (S.D.V.); (P.P.); (M.A.); (F.M.); (K.F.S.); (L.S.); (P.C.-L.)
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium;
| | - Jana Hundertmark
- Department of Hepatology & Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany; (J.H.); (M.K.)
| | - Marlene Kohlhepp
- Department of Hepatology & Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany; (J.H.); (M.K.)
| | - Nurdan Guldiken
- Department of Medicine III, RWTH-University Hospital Aachen, 52074 Aachen, Germany; (T.P.); (N.G.); (C.T.); (T.L.); (P.S.)
| | - Philippe Pujuguet
- Galapagos SA, 102 avenue Gaston Roussel, 93230 Romainville, France; (S.D.V.); (P.P.); (M.A.); (F.M.); (K.F.S.); (L.S.); (P.C.-L.)
| | - Marielle Auberval
- Galapagos SA, 102 avenue Gaston Roussel, 93230 Romainville, France; (S.D.V.); (P.P.); (M.A.); (F.M.); (K.F.S.); (L.S.); (P.C.-L.)
| | - Florence Marsais
- Galapagos SA, 102 avenue Gaston Roussel, 93230 Romainville, France; (S.D.V.); (P.P.); (M.A.); (F.M.); (K.F.S.); (L.S.); (P.C.-L.)
| | - Kenji F. Shoji
- Galapagos SA, 102 avenue Gaston Roussel, 93230 Romainville, France; (S.D.V.); (P.P.); (M.A.); (F.M.); (K.F.S.); (L.S.); (P.C.-L.)
| | - Laurent Saniere
- Galapagos SA, 102 avenue Gaston Roussel, 93230 Romainville, France; (S.D.V.); (P.P.); (M.A.); (F.M.); (K.F.S.); (L.S.); (P.C.-L.)
| | - Christian Trautwein
- Department of Medicine III, RWTH-University Hospital Aachen, 52074 Aachen, Germany; (T.P.); (N.G.); (C.T.); (T.L.); (P.S.)
| | - Tom Luedde
- Department of Medicine III, RWTH-University Hospital Aachen, 52074 Aachen, Germany; (T.P.); (N.G.); (C.T.); (T.L.); (P.S.)
| | - Pavel Strnad
- Department of Medicine III, RWTH-University Hospital Aachen, 52074 Aachen, Germany; (T.P.); (N.G.); (C.T.); (T.L.); (P.S.)
| | - Reginald Brys
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium;
| | - Philippe Clément-Lacroix
- Galapagos SA, 102 avenue Gaston Roussel, 93230 Romainville, France; (S.D.V.); (P.P.); (M.A.); (F.M.); (K.F.S.); (L.S.); (P.C.-L.)
| | - Frank Tacke
- Department of Hepatology & Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany; (J.H.); (M.K.)
| |
Collapse
|
6
|
Mahmud ZA, Jenkins L, Ulven T, Labéguère F, Gosmini R, De Vos S, Hudson BD, Tikhonova IG, Milligan G. Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84. Sci Rep 2017; 7:17953. [PMID: 29263400 PMCID: PMC5738391 DOI: 10.1038/s41598-017-18159-3] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 12/05/2017] [Indexed: 12/18/2022] Open
Abstract
Medium chain fatty acids can activate the pro-inflammatory receptor GPR84 but so also can molecules related to 3,3′-diindolylmethane. 3,3′-Diindolylmethane and decanoic acid acted as strong positive allosteric modulators of the function of each other and analysis showed the affinity of 3,3′-diindolylmethane to be at least 100 fold higher. Methyl decanoate was not an agonist at GPR84. This implies a key role in binding for the carboxylic acid of the fatty acid. Via homology modelling we predicted and confirmed an integral role of arginine172, located in the 2nd extracellular loop, in the action of decanoic acid but not of 3,3′-diindolylmethane. Exemplars from a patented series of GPR84 antagonists were able to block agonist actions of both decanoic acid and 3,3′-diindolylmethane at GPR84. However, although a radiolabelled form of a related antagonist, [3H]G9543, was able to bind with high affinity to GPR84, this was not competed for by increasing concentrations of either decanoic acid or 3,3′-diindolylmethane and was not affected adversely by mutation of arginine172. These studies identify three separable ligand binding sites within GPR84 and suggest that if medium chain fatty acids are true endogenous regulators then co-binding with a positive allosteric modulator would greatly enhance their function in physiological settings.
Collapse
Affiliation(s)
- Zobaer Al Mahmud
- Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow Glasgow, G12 8QQ, Scotland, United Kingdom
| | - Laura Jenkins
- Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow Glasgow, G12 8QQ, Scotland, United Kingdom
| | - Trond Ulven
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark
| | - Frédéric Labéguère
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230, Romainville, France.,Evotec, 195 Route d'Espagne, 31100, Toulouse, France
| | - Romain Gosmini
- Galapagos SASU, 102 Avenue Gaston Roussel, 93230, Romainville, France
| | - Steve De Vos
- Galapagos NV, Generaal De Wittelaan L11 A3, 2800, Mechelen, Belgium
| | - Brian D Hudson
- Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow Glasgow, G12 8QQ, Scotland, United Kingdom
| | - Irina G Tikhonova
- School of Pharmacy, Medical Biology Centre, Queen's University Belfast, Belfast, BT9 7BL, United Kingdom
| | - Graeme Milligan
- Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow Glasgow, G12 8QQ, Scotland, United Kingdom.
| |
Collapse
|
7
|
Pizzonero M, Dupont S, Babel M, Beaumont S, Bienvenu N, Blanqué R, Cherel L, Christophe T, Crescenzi B, De Lemos E, Delerive P, Deprez P, De Vos S, Djata F, Fletcher S, Kopiejewski S, L’Ebraly C, Lefrançois JM, Lavazais S, Manioc M, Nelles L, Oste L, Polancec D, Quénéhen V, Soulas F, Triballeau N, van der Aar EM, Vandeghinste N, Wakselman E, Brys R, Saniere L. Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic. J Med Chem 2014; 57:10044-57. [DOI: 10.1021/jm5012885] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
| | - Sonia Dupont
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | - Marielle Babel
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | | | | | - Roland Blanqué
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | - Laëtitia Cherel
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | | | | | - Elsa De Lemos
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | | | - Pierre Deprez
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | - Steve De Vos
- Galapagos, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium
| | - Fatoumata Djata
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | | | | | | | | | | | - Murielle Manioc
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| | - Luc Nelles
- Galapagos, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium
| | - Line Oste
- Galapagos, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium
| | - Denis Polancec
- Fidelta, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia
| | | | | | | | | | | | | | - Reginald Brys
- Galapagos, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium
| | - Laurent Saniere
- Galapagos, 102 Avenue
Gaston Roussel, 93230 Romainville, France
| |
Collapse
|
8
|
Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N, Vayssiere B, De Vos S, Fletcher S, Brys R, van 't Klooster G, Feyen JHM, Menet C. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013; 191:3568-77. [PMID: 24006460 DOI: 10.4049/jimmunol.1201348] [Citation(s) in RCA: 159] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The JAKs receive continued interest as therapeutic targets for autoimmune, inflammatory, and oncological diseases. JAKs play critical roles in the development and biology of the hematopoietic system, as evidenced by mouse and human genetics. JAK1 is critical for the signal transduction of many type I and type II inflammatory cytokine receptors. In a search for JAK small molecule inhibitors, GLPG0634 was identified as a lead compound belonging to a novel class of JAK inhibitors. It displayed a JAK1/JAK2 inhibitor profile in biochemical assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of ∼30-fold for JAK1- over JAK2-dependent signaling. GLPG0634 dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro. GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repression of Mx2 expression in leukocytes. Oral dosing of GLPG0634 in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent reduction of the disease progression. Paw swelling, bone and cartilage degradation, and levels of inflammatory cytokines were reduced by GLPG0634 treatment. Efficacy of GLPG0634 in the collagen-induced arthritis models was comparable to the results obtained with etanercept. In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases.
Collapse
Affiliation(s)
- Luc Van Rompaey
- Departement of In Vitro Pharmacology, Galapagos NV, 2800 Mechelen, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Merchiers P, Spittaels K, Hinnekint S, De Vos S, Staes M, Cohen A, Mercken M, De Strooper B, Brown R. P4-373 A knock down screen for identification of putative Alzheimer's disease modifying drugable genes that modulate amyloid levels. Neurobiol Aging 2004. [DOI: 10.1016/s0197-4580(04)81931-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|